Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Realty Income Corp (O) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Realty Income CorpTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Realty Income Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Realty Income Corp trades at $65.09 (market cap $60.60B), while State Street SPDR S&P Biotech ETF trades at $152.12. The key difference: Realty Income Corp pays a 5% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.

OXBI
Market Cap
$60.60B
Sector
Real EstateBroad Market / Factor
52-Week High
$67.56$164.28
52-Week Low
$55.93$85.16
Enterprise Value
$90.40B
Dividend Yield
5%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Realty Income Corp

No Aura AI signal available yet.

State Street SPDR S&P Biotech ETF

XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.

Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Realty Income Corp

Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.

Read more on O

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI